However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

At the current share price, its dividend yields just 1.8%, which may look unimpressive at first. However, the company has ...

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

Despite the firm again raising its revenue and GAAP guidance, we’ve made only minor changes to our model in the long run.

Your head hurts. Maybe you were staring at your computer or phone too long. Or you skipped breakfast, didn’t sleep well, or got stressed fighting traffic. But now that it’s here, what can you do to ...

AbbVie Inc. ABBV reported adjusted earnings of $3.00 per share for the third quarter of 2024, beating the Zacks Consensus Estimate of $2.92. The reported earnings also exceeded the company’s ...

Botox continues to generate billions of dollars each year. Sales of migraine drugs Ubrelvy and Qulipta are growing at double-digit percentage rates. More winners could be on the way. AbbVie's ...